Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04378777 · ClinicalTrials.gov registry record
Immunophenotyping Assessment in a COVID-19 Cohort
A clinical trial, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- 1,227
- Enrollment target
NCT04378777: Completed study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT04378777 is a clinical trial that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 1,227 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04378777 has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- 1,227 participants
- Enrollment target
Study Summary
This surveillance study will collect detailed clinical, laboratory, and radiographic data in coordination with biologic sampling of blood and respiratory secretions and viral shedding in nasal secretions in order to identify immunophenotypic and genomic features of COVID-19 -related susceptibility and/or progression. The aim: for the results obtained from this study to assist in generating hypotheses for effective host-directed therapeutic interventions, to help to prioritize proposals for such interventions, and/or optimize timing for administration of host-response directed therapeutics.
Primary Outcome
The incidence of mortality in the first 28 days.
Interventions
- PROCEDURE Biological sample collection
- PROCEDURE Data Collection: Clinical Care Assessments
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,227 participants |
| Start Date | 2020-05-01 |
| Est. Completion | 2022-04-21 |
What the finished NCT04378777 record still lists
NCT04378777 is an observational study that tracks outcomes without assigning an intervention. Its 1,227 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Biological sample collection is the first listed.
NCT04378777 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04378777 about?
NCT04378777 is a clinical study titled "Immunophenotyping Assessment in a COVID-19 Cohort". This surveillance study will collect detailed clinical, laboratory, and radiographic data in coordination with biologic sampling of blood and respiratory secretions and viral shedding in nasal secretions in order to identify immunophenotypic and genomic features of COVID-19 -related susceptibility a...
What is the current status of trial NCT04378777?
This trial is currently completed. The enrollment target is 1,227 participants. The study started on 2020-05-01. Estimated completion is 2022-04-21.
What interventions are being tested in trial NCT04378777?
The interventions under investigation include: Biological sample collection (PROCEDURE), Data Collection: Clinical Care Assessments (PROCEDURE).
Who is sponsoring clinical trial NCT04378777?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05946044 · 1,230 participants · NA
The Osteoarthritis Prevention Study
- NCT06787937 · 1,230 participants · NA
Communicating About Nicotine Reduction in Cigarettes
- NCT05456841 · 1,232 participants · NA
Empathic Communication Skills (ECS) Training
- NCT06921785 · 1,220 participants · Phase 3
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI